CED Life Science Conference 2017 - Innovation Room
Sub-sector: Medical Device
Year Founded: 2012
Ovarian cancer affects 1 in 74 women in their lifetime, is the 4th deadliest cancer for women and one of the few remaining without a reliable early detection tool. MKT's patent pending device and procedure have been manufactured under FDA design controls with a ISO-13485 registered firm with line of sight to 510(k) approval through a clear predicate. MKT conducted an IRB approved test which successfully collected 18 samples from 5 patients, The reimbursement infrastructure is in place to enable over $5,000 per test, and considering pap smears (an early detection tool for cervical cancer) has 29.4M tests done per year, we believe the market potential to be very large.
KEY MILESTONES TO DATE
- Funding: <$1MM
- Successful testing of product within IRB approved study on 5 patients
- Collecting 18 samples which showed excellent matching to corresponding pathology from hysterectomy
- Letter from FDA indicating 510k path as appropriate one
- Patent filings globally
Bio Tech Trans, 8 Rivers Capital
South Windsor, CT
Learn more about the CED Life Science Conference.